ReviewFrontiers in oncology2015
Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies.
Review in Frontiers in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Department of Hematology, The Second Affiliated Hospital of Kunming Medical University.
The Second Affiliated Hospital of Kunming Medical University
Who cites it
24 citing papers in PubMed.
- Trial
- Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia.Frontiers in immunology · 2025Trial
- Trial
- A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients.Human vaccines & immunotherapeutics · 2021Trial
- Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia.Diseases (Basel, Switzerland) · 2025Article
- Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: perspectives from a European expert panel.Frontiers in oncology · 2025Article
- The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia.Scientific reports · 2024Article
- Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate.Scientific reports · 2024Article
- Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.Blood cancer discovery · 2023Article
- Novel Aminopyrimidine-2,4-diones, 2-Thiopyrimidine-4-ones, and 6-Arylpteridines as Dual-Target Inhibitors of BRD4/PLK1: Design, Synthesis, Cytotoxicity, and Computational Studies.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience.Clinical case reports · 2022Article
- Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2022Review
- Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study.Frontiers in oncology · 2022Article
- Redefining Remission Induction Chemotherapy Ineligibility by Early Mortality in De Novo Acute Myeloid Leukemia.Journal of clinical medicine · 2021Article
- Immunorelated gene polymorphisms associated with acute myeloid leukemia.Clinical and experimental immunology · 2020Article
- Article
- Dendrogenin A synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo.Cancers · 2020Article
- Epigenetic polypharmacology: A new frontier for epi-drug discovery.Medicinal research reviews · 2020Review
- Using Social Media to Uncover Treatment Experiences and Decisions in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Who Are Ineligible for Intensive Chemotherapy: Patient-Centric Qualitative Data Analysis.Journal of medical Internet research · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Although acute myeloid leukemia (AML) is primarily a disease of older adults (age ≥60 years), the optimal treatment for older adults remains largely undefined. Intensive chemotherapy is rarely beneficial for frail older adults or those with poor-risk disease, but criteria that define fitness and/or appropriateness for intensive chemotherapy remain to be standardized. Evaluation of disease-related and patient-specific factors in the context of clinical decision making has therefore been largely subjective. A uniform approach to identify those patients most likely to benefit from intensive therapies is needed. Here, we review currently available objective measures to define older adults with AML who are ineligible for intensive chemotherapy, and discuss promising investigational approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.